EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Therapies in AL Amyloidosis—A Glimpse to the Future

Arnon Haran, Iuliana Vaxman, Moshe E Gatt iD, Eyal Lebel

Cancers · 22.04.2024 · 16 (8) · 1605

DOI: 10.3390/cancers16081605 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.04.2024. Verfasst von Arnon Haran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains in target organs, leading to multi-organ dysfunction. Treatment approaches have historically mirrored but lagged behind those of multiple myeloma (MM). Recent advancements in MM immunotherapy are gradually being evaluated and adopted in AL amyloidosis. This review explores the current state of immunotherapeutic strategies in AL amyloidosis, including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapy. We discuss the unique challenges and prospects of these therapies in AL amyloidosis, including the exposure of frail AL amyloidosis patients to immune-mediated toxicities such as cytokine release syndrome (CRS) and immune effector-cell-associated neurotoxicity syndrome (ICANS), as well as their efficacy in promoting rapid and deep hematologic responses. Furthermore, we highlight the need for international initiatives and compassionate programs to provide access to these promising therapies and address critical unmet needs in AL amyloidosis management. Finally, we discuss future directions, including optimizing treatment sequencing and mitigating toxicities, to improve outcomes for AL amyloidosis patients.

Schlagwörter

Stichwörter der Autor:innen

amyloidosisbispecific antibodieschimeric antigen receptor T cellsimmunotherapylight chainplasma cell dyscrasia

Autor:innen und Institutionen

  • Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel.
  • Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 49100, Israel.

ORCID-Profile: Moshe E Gatt

Zitieren

APA

Haran, A., Vaxman, I., Gatt, M. E., & Lebel, E. (2024). Immune Therapies in AL Amyloidosis—A Glimpse to the Future. Cancers, 16(8), 1605. https://doi.org/10.3390/cancers16081605

Vancouver

Haran A, Vaxman I, Gatt ME, Lebel E. Immune Therapies in AL Amyloidosis—A Glimpse to the Future. Cancers. 2024;16(8):1605. doi:10.3390/cancers16081605

BibTeX
@article{Haran2024,
  author = {Haran, Arnon and Vaxman, Iuliana and Gatt, Moshe E and Lebel, Eyal},
  title = {Immune Therapies in AL Amyloidosis—A Glimpse to the Future},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {8},
  pages = {1605},
  doi = {10.3390/cancers16081605}
}
Kostenlos starten →